Indivior (INDV)

Nasdaq Health Care Pharmaceuticals S&P SmallCap 600
$36.28
+0.91 (+2.57%)
Close of Nov 02, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Trailing 12-month EPS
$3.58
Diluted, last four reported quarters

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Oct 29, 2026Sep/2026$0.93$1.32+41.9%

Our record of INDV's reports since we began tracking; it grows each quarter.

Latest results, in brief

All INDV 8-K briefs →
Oct 29, 7:00 AM ET

Indivior Q3 revenue rises 13% to $356 million; net income $137 million

Positive earnings 2.02

Indivior reported third-quarter 2026 results with total net revenue of $356 million, up 13% year over year, and GAAP net income of $137 million ($1.12 diluted EPS), compared with $42 million a year earlier. The company said it is on track for its previously communicated 2026 guidance as a standalone company, but that guidance will no longer apply if its merger with Supernus closes as expected on November 2, 2026.

  • Total SUBLOCADE net revenue was $267 million, up 22% year over year; U.S. SUBLOCADE net revenue rose 24% to $252 million.
  • Adjusted EBITDA was $211 million, up 76% from $120 million a year earlier; GAAP operating expenses fell 33% to $125 million.
  • Cash and investments totaled $332 million at September 30, 2026.
  • Merger with Supernus is expected to close November 2, 2026; the combined company is to trade as SUPN from November 3, 2026.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$356.00M+13.4% $1.12+239.4% $137.00M38.5%
Jun 2026$343.00M+13.6% $0.98+600.0% $122.00M35.6%
Mar 2026$317.00M+19.2% $0.69+81.6% $89.00M28.1%
Dec 2025$358.00M+19.7% $0.79+393.8% $102.00M28.5%
Sep 2025$314.00M+2.3% $0.33+106.2% $42.00M13.4%
Jun 2025$302.00M+1.0% $0.14— $18.00M6.0%
Mar 2025$266.00M-6.3% $0.38-15.6% $47.00M17.7%
Dec 2024$299.00M— $0.16— $21.00M7.0%

From Indivior's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$1.24B+4.3% $1.64+3180.0%16.9%
FY2024$1.19B+8.7% $0.05—0.6%
FY2023$1.09B+21.3% $-0.92—-11.5%
FY2022$901.00M— $-0.30—-4.7%

Frequently asked questions

When is Indivior's next earnings date?

Indivior has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Indivior earn last quarter?

For the quarter ended Sep 2026, Indivior reported diluted EPS of $1.12 (+239.4% year over year) on revenue of $356.00M (+13.4%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.